Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.

ABSTRACT:

Purpose of review

Cancer vaccines are facing renewed interest, thanks to the progress recently achieved in the immunotherapy field, including the success of immune checkpoint inhibitors (CPIs). The advances in understanding the CPI mode of action revealed a central role of neoantigens for the outcome of such treatments. Neoantigens became the preferred antigens for cancer vaccines and have been evaluated in several clinical trials. Here, we review the recent results from neoantigen-based vaccines in melanoma patients and discuss avenues for improvement.

Recent findings

The importance of neoantigens for tumor control comes from the positive correlation between tumor mutational burden (TMB) and response to CPI. Preclinical studies have proved the effectiveness of neoantigen va

SUBMITTER: D'Alise AM 

PROVIDER: S-EPMC9894148 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature